Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer

Read full text Summarise with VIRAT
Authors: Larissa Sena Teixeira Mendes, Peter Dutey‐Magni, Emily Grist, Ashwin Sachdeva, Sara Santos Vidal, Sharanpreet Kall Lall, Marina Parry, Claire L. Amos, Nafisah B Atako, Anna Wingate, Daniel Wetterskog, Matthew Robert Sydes
+8 more Chris C. Parker, Noel William Clarke, Christopher J. Sweeney, Mahesh Parmar, Louise Clare Brown, Nicholas David James, Daniel Maurice Berney, Gerhardt Attard
Cited by: 0
References: 6

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Prostate cancers with high proliferation rates have shorter survival times but when spread has occurred (metastatic), there is increased sensitivity to hormone therapy with abiraterone. .

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Cancer Lipids and Metabolism

Publication details

Journal / source
Journal of Clinical Investigation
Volume
136
Issue
10
Pages
e203201
Publication date
31 March 2026
Language
EN